ReviewCureus2022
Dengue & COVID-19: A Comparison and the Challenges at Hand.
Review in Cureus, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Clinical Manifestations and Immunological Impacts in Co-Infections and Sequential Infections of SARS-CoV-2 and Arboviruses.Current microbiology · 2026Review
- Furin as a Novel Pan-Viral Therapeutic Target: Implications for Dengue and SARS-CoV-2.Viruses · 2026Review
- Article
- Assessing the global dengue burden: Incidence, mortality, and disability trends over three decades.PLoS neglected tropical diseases · 2025Observational
- Spatiotemporal expansion of dengue in Brazilian Amazon between 2001 and 2021.Scientific reports · 2025Article
- SARS-CoV-2 spike antibodies cross-react with dengue virus and enhance infectionFrontiers in immunology · 2025Article
- Exploring the Contrasts and Similarities of Dengue and SARS-CoV-2 Infections During the COVID-19 Era.International journal of molecular sciences · 2024Review
- Dengue fever coinfection in COVID-19 era: A public health concern.Health science reports · 2024Article
- Dengue Mimickers: Which Clinical Conditions Can Resemble Dengue Fever?Revista da Sociedade Brasileira de Medicina Tropical · 2024Review
- Expanded dengue syndrome in diabetic patient with history of COVID-19 infection: a case report.Annals of medicine and surgery (2012) · 2023Article
- The effects of the COVID-19 pandemic on dengue cases in Malaysia.Frontiers in public health · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The COVID-19 pandemic caused by SARS-CoV-2 spread across many countries between 2020 and 2022. The similarities in clinical presentation with other endemic diseases pose a challenge to physicians in effectively diagnosing and treating the infection. Approximately 129 nations have a risk of dengue infection, and more than 100 of those are endemic to dengue. During the COVID-19 pandemic, the number of dengue cases decreased in many countries owing to the isolation measures followed. However, the common clinical presentation between them has led to misdiagnosis. Both COVID-19 and dengue fever cause a surge in pro-inflammatory cytokines and chemokines, thus sharing a common pathophysiology. False positive serological test results also posed difficulty differentiating between COVID-19 and dengue fever. This review aims to compare the clinical features, pathophysiology, and immune response between dengue and COVID-19, to benefit public health management during the pandemic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.